Pharmaceutical Grade Lactic Acid

Pharmaceutical Grade Lactic Acid is supplied as a purified aqueous solution of 2-hydroxypropanoic acid with the CAS 79-33-4 designation for the L(+) enantiomer and CAS 50-21-5 for the racemic mixture. Compounding pharmacies and finished-dose manufacturers typically order the product by concentration-grade models such as L(+)-Lactic Acid 90% USP-NF/Ph. Eur. or L(+)-Lactic Acid 88% JP. The nominal total acid content is controlled between 88.0% and 92.0% w/w, expressed as C₃H₆O₃, but the solution is not a simple monomer; it exists as an equilibrium mixture of free lactic acid, linear condensation dimers, trimers, and water. Pharmaceutical grade status is defined less by total acidity and more by the absence of bacterial endotoxins, heavy metals, residual solvents, and the D-lactic acid fraction. A representative release profile specifies L-isomer ≥ 97.5% and D-isomer ≤ 2.5%, whereas technical or food acidulants frequently leave the enantiomeric ratio uncontrolled or wider. This distinction matters in parenteral and dialysis applications because D-lactate is metabolised more slowly in humans than L-lactate.

Manufacturing of pharmaceutical grade lactic acid normally proceeds by anaerobic homofermentative conversion of glucose or sucrose using selected Lactobacillus strains, followed by calcium lactate precipitation at pH 10–11 with calcium hydroxide. The calcium lactate cake is washed, acidified with sulfuric acid, and filtered to remove calcium sulfate. The clarified acid is then processed through activated carbon, cation-exchange resin, and anion-exchange resin to reduce colour, iron, sulfate, and residual sugars, and concentrated in wiped-film evaporators at 60–80 °C under reduced pressure. The final solution is passed through a 0.2 µm sterilising-grade filter into depyrogenated fluorinated high-density polyethylene packaging. Packaging models include 30 kg drums, 250 kg drums, and 1,250 kg intermediate bulk containers with nitrogen blanketing at 0.1–0.3 bar. The ion-exchange and carbon-treatment sequence is operationally critical: inadequate resin regeneration or aged carbon beds raise total organic carbon, endotoxin, and colour, and can release leached monomers that later fail Ph. Eur. 2.4.24 residual solvent or USP <467> testing.

What Specifications Define Pharmaceutical Grade Lactic Acid?

A representative release certificate for L(+)-lactic acid 90% pharmaceutical grade includes total acidity, enantiomeric purity, colour, chloride, sulfate, iron, arsenic, residual solvents, and microbial attributes. Total acidity is determined by acid-base titration with 1.0 mol/L sodium hydroxide using a potentiometric endpoint, with an acceptance window of 88.0–92.0% w/w; enantiomeric purity is confirmed by chiral ligand-exchange HPLC or by enzymatic D-lactate dehydrogenase assay. Colour is controlled at ≤ 50 APHA against platinum-cobalt reference solutions; chloride and sulfate are limited because chloride accelerates corrosion in 316L stainless steel transfer lines and sulfate can precipitate in calcium-containing dialysate concentrates. The typical chloride limit is ≤ 0.002% and sulfate ≤ 0.005%. Iron is held at ≤ 5 ppm to avoid discolouration in formulations containing phenolic antioxidants, while arsenic is limited to ≤ 1 ppm and class 1 heavy metals are governed by ICH Q3D Option 1. Endotoxin and microbial limits differentiate pharmaceutical lactic acid from food grade even when the acid content is identical.

The specification values in the above table are representative release targets for a parenteral-excipient model and should be verified against the current Ph. Eur. monograph 01/2018:0656, USP-NF Lactic Acid monograph, and JP Lactic Acid monograph. Manufacturers may tighten individual limits for specific injectable or dialysis products; for example, endotoxin may be controlled at ≤ 0.1 EU/mg when the downstream formulation already contains an endotoxin-sensitive peptide. Each batch is accompanied by a certificate of analysis that records water content, optical rotation, and non-volatile residue; compendial identity is confirmed by retention-time agreement in liquid chromatography and by the colorimetric reaction of lactate with iron(III) chloride. The product should not be released to pharmaceutical manufacture without documented absence of citric, oxalic, tartaric, and phosphoric acids, which are separately limited in the monograph to ensure the lactic acid has not been blended with cheaper acidulants.

Chiral HPLC for the release of L-lactic acid typically uses a ligand-exchange column maintained at 30 °C with 5 mM copper(II) sulfate mobile phase and ultraviolet detection at 254 nm; the resolution between D- and L-lactate is typically ≥ 1.5. For confirmatory identity, compendial optical rotation is measured on the neat solution by Ph. Eur. 2.2.7, and total organic carbon after dilution to 10% w/v is used as an in-process check of purification quality. Conductivity after 10% w/v dilution is monitored in release to detect excessive ionic contamination from incomplete ion-exchange rinsing. The solution is also inspected for visible particulate matter after dilution because pharmaceutical grade lactic acid is intended for downstream sterile filtration; any visible fibres or resin fragments require re-filtration and a deviation investigation.

Physically, the 90% w/w solution is a colourless to pale-yellow syrupy liquid with density 1.20–1.22 g/cm³ at 25 °C, refractive index 1.426–1.432, and dynamic viscosity 40–80 mPa·s at 25 °C. The freezing point remains below -10 °C for the 88–92% concentration range, which permits unheated tank transfer in cold storage areas. Hygroscopicity is a critical processing variable: a 90% solution stored in an open vessel at 25 °C and 75% RH absorbs atmospheric moisture and shifts the free-acid/oligomer equilibrium; repeated partial withdrawal from drums without nitrogen overlay can increase water content by 0.5–1.0% w/w over 30 days in humid production areas. Transfer lines are therefore constructed from 316L stainless steel or PTFE-lined pipework with EPDM or fluoropolymer gaskets, and centrifugal pump seals are specified for acid service at pH < 2.

When Lactic Acid Functions as a Parenteral Excipient and Dialysis Buffer Precursor

In injectable manufacture, pharmaceutical grade lactic acid is diluted to 0.1–2.0% w/v and added to the aqueous phase before the active pharmaceutical ingredient to depress pH into a stability window of 3.0–4.5. The weak acid has a pKa of 3.86 at 25 °C; therefore it provides useful buffer capacity in this acidic range but negligible capacity at physiological pH 7.4. Dosing is performed by slow addition to water under continuous agitation, never water to concentrated acid, because the dilution exotherm can locally exceed 8 °C in a 10% w/v preparation. Production vessels larger than 500 L typically use jacket cooling with 5–15 °C coolant and recirculation loops at 1–2 m/s to avoid pH overshoot. In-line pH probes with automatic temperature compensation are positioned downstream of the dosing point, and the addition is stopped when the product-specific pH endpoint is reached.

For peptide or protein formulations where chloride ions are undesirable, lactic acid is selected over hydrochloric acid at concentrations below 0.5% w/v. The final formulation is often re-adjusted to pH 4.0–5.5 with dilute sodium hydroxide, and compatibility studies are required because lactic acid can chelate divalent cations and may affect the solubility of calcium or zinc-containing actives. In parenteral nutrition, lactic acid is used less often than citric or acetic acid, but it appears in a narrow set of sterile solutions where its metabolism to pyruvate is acceptable. Any use in injectable products must be supported by bacterial endotoxin release testing by Ph. Eur. 2.6.14 or USP <85>, because the route of administration makes endotoxin compliance non-negotiable.

In haemodialysis and peritoneal dialysis, L(+)-lactic acid serves as an acidifying agent and bicarbonate precursor in acidified concentrate formulations. The acidified concentrate is held at pH 2.8–3.5 to prevent precipitation of calcium carbonate and magnesium carbonate during storage, then proportioned with bicarbonate concentrate in the dialysis machine. Final dialysate lactate concentrations commonly range from 35 to 40 mmol/L, which corresponds to a lactic acid concentration in the liquid concentrate depending on the dilution ratio; a 1:32.775 proportioning system requires a lactic acid concentrate concentration near 1.1–1.3 mol/L. Ultrapure dialysate is specified to an endotoxin level of ≤ 0.03 EU/mL, so the incoming pharmaceutical grade lactic acid must contribute negligible endotoxin after dilution. Technical or food grade lactic acid with uncontrolled endotoxin can overload the final dialyser and trigger an inflammatory response; therefore substitution is not acceptable without a documented ultrafiltration and endotoxin-reduction step.

In absorbable polymer synthesis, pharmaceutical grade lactic acid is the monomer source for lactide and, after dimerisation, for poly(L-lactic acid) and poly(lactic-co-glycolic acid). Ring-opening polymerisation with stannous octoate catalyst requires an L-isomer content exceeding 99.0% for semi-crystalline PLLA; the D-isomer threshold of ≤ 2.5% in the 90% pharmaceutical solution is only a starting point. If technical grade lactic acid with D-isomer > 5% is used, the resulting polymer shows depressed melting point, reduced crystallinity, and faster hydrolytic degradation, which alters drug-release kinetics in PLGA microsphere products. Metal impurities such as iron, aluminium, and tin are also limited to prevent catalyst deactivation and polymer discolouration. In this application, the document trail matters as much as the chemical profile: batch-to-batch variance in residual sugars or sulfated ash changes lactide yield and optical rotation, so pharmaceutical grade material is used under change control.

Operational boundaries are defined by the corrosive and hygroscopic nature of the material. It is incompatible with strong oxidisers, concentrated mineral acids, aluminium, and carbon steel; neutralisation with amines or alkali carbonates is strongly exothermic and must be cooled. Storage is recommended at 15–25 °C in tightly closed, nitrogen-flushed containers; repeated exposure to air above 60% RH increases water content and oligomer equilibration, and prolonged storage above 40 °C can discolour the solution and increase lactide formation. If the material is frozen, thawing may produce temporary stratification; bulk tanks should be recirculated before sampling to ensure a representative release sample. These limits are not marketing statements; they are derived from the same specifications that pharmaceutical manufacturers audit under excipient supplier qualification.

Distinction Between Pharmaceutical, Food, and Technical Lactic Acid Grades

Total acidity alone cannot differentiate pharmaceutical grade from food or technical material. Two drums each marked 90% lactic acid can differ by orders of magnitude in endotoxin, heavy metal, residual solvent, and microbial load. Food grade lactic acid certified to FCC or JECFA is suitable for acidification of fermented meat, dairy products, and confectionery, but it is not tested for bacterial endotoxins and often allows higher total aerobic microbial count. Technical grade lactic acid is a commodity product used in metal cleaning, oilfield stimulation, textile mordanting, and industrial neutralisation; it may contain residual reducing sugars, sulfated ash, and colour bodies that require distillation, ion exchange, or carbon treatment before pharmaceutical consideration. Reagent grade lactic acid may meet assay and titration specifications but is generally not tested for endotoxin, particulate matter, or residual solvents under pharmaceutical conditions.

When a manufacturer considers replacing pharmaceutical grade with food or technical material, the excipient risk assessment must address the route of administration, the presence of D-lactic acid, endotoxin, elemental impurities under ICH Q3D, residual solvent class limits under Ph. Eur. 2.4.24 or USP <467>, and microbial quality under Ph. Eur. 2.6.12/2.6.13 or USP <61>. Process validation batches must be repeated against USP <85>, USP <232>/<233>, and USP <467> before release. Food grade lactic acid can serve as a starting material for pharmaceutical grade after additional purification, but it must be re-qualified, not simply relabelled. This grade distinction, rather than the nominal acid concentration, is the principal specification that purchasing and quality units must control.